News Related to Mixed Phenotype Acute Leukemia

Related coverage linked through entity extraction aliases.

First-in-World Trial Tests Subcutaneous Blinatumomab for Rare Mixed-Phenotype Acute Leukemia

Feb 21, 2026

West Virginia University Cancer Institute has dosed the first patient in a phase 1/2 trial evaluating subcutaneous blinatumomab for CD19-positive mixed-phenotype acute leukemia, a rare disease with no FDA-approved therapies. The first patient achieved complete remission after one cycle.

First Patient Achieves Remission With Subcutaneous Blinatumomab in Ultra-Rare MPAL

Feb 20, 2026

A Phase II trial led by WVU Cancer Institute reports the first-ever use of subcutaneous blinatumomab in CD19-positive mixed phenotype acute leukemia, with the first patient achieving complete remission after one cycle.